View Exam | PowerPak

1. Why does the US Food and Drug Administration require a Risk Evaluation and Mitigation Strategy (REMS) program for mycophenolic acid (MPA) prescription?

A. Risks to pregnant women and the developing fetus when MPA is taken by a pregnant woman B. Risks to male partners of women taking MPA C. Risks to only the developing fetus when MPA is taken by pregnant woman D. Risks to pregnant women only when taking MPA E. Unsure

2. Patient education is an important component of the Mycophenolate REMS program. Which of the following types of counseling should be given to female patients of reproductive potential who may be started on MPA therapy?

A. Financial and family planning/pregnancy counseling B. Financial and contraceptive counseling C. Family planning/pregnancy and contraceptive counseling D. Child care and family planning/pregnancy counseling E. Unsure

3. Upon learning that a female patient who is taking MPA becomes pregnant, the pregnancy should be reported to the Mycophenolate Pregnancy Registry. Who can report the pregnancy?

A. Only the prescriber B. Only the patient's OB/GYN C. The patient D. Any healthcare professional E. Unsure

4. The Centers for Disease Control and Prevention (CDC) differentiate between uncomplicated and complicated (i.e., acute or chronic graft failure, rejection, or cardiac allograft vasculopathy) cases of solid organ transplant. Which of the following contraception methods would be considered an unacceptable health risk in a patient with a complicated case of solid organ transplant per the CDC?

A. Copper-containing intrauterine device (IUD) B. Levonorgestrel-releasing IUD C. Combined hormonal contraceptives D. Depot medroxyprogesterone acetate E. Unsure

5. The Mycophenolate REMS program focuses on multiple stakeholders: prescribers, patients, and other healthcare professionals. Which of the following best describes participation in the Mycophenolate REMS program?

A. Participation is encouraged for all prescribers, patients, and other healthcare professionals B. Participation is required for all prescribers, patients, and other healthcare professionals C. Participation is required for all prescribers and encouraged for other healthcare professionals and patients D. Participation is required for all prescribers and other healthcare professionals and encouraged for patients E. Unsure

6. Under which of the following circumstances would your recommend that a provider report a pregnancy to the Mycophenolate Pregnancy Registry?

A. A female partner of a man currently taking MPA has a positive pregnancy test B. A woman who stopped MPA therapy 2 weeks ago has a positive pregnancy test C. A woman who stopped MPA therapy 8 weeks ago has a positive pregnancy test D. A female partner of a man who stopped MPA therapy 5 weeks ago has a positive pregnancy test E. Unsure

7. AB is a 25-year-old woman with dilated cardiomyopathy who is undergoing evaluation for a heart transplant. The transplant physician reviews the immunosuppressive drug regimen of tacrolimus, MPA, and prednisone that she will be prescribed post-transplant. When should the physician first discuss the risks of MPA?

A. Before prescribing MPA B. If/When the patient asks about becoming pregnant C. After the patient becomes pregnant D. When the patient fills the prescription for MPA E. Unsure

8. AB indicates that she is single and has been dating. She would like to get pregnant and have children in the future. Which option when used alone is the most effective method of contraception and best choice for AB?

A. Birth control pill B. IUD C. Condom D. Tubal sterilization E. Unsure

9. A pharmacy student is interning at a local pharmacy where AB picks up her prescriptions. The pharmacy intern notices MPA on AB's medication profile and recalls that there is a REMS program associated with this medication. What Mycophenolate REMS literature should the intern give to the patient?

A. Medication guide at initial fill only B. Medication guide at initial fill and at refills C. Patient information brochure at initial fill only D. Patient information brochure at initial fill and all refills E. Unsure

10. AB is 3 years post-transplant. She has been taking her immunosuppressive regimen, which includes MPA, as ordered by her transplant physician. She missed her period and recently took a pregnancy test that confirmed she is pregnant. Which is a method to report a pregnancy to the Mycophenolate Pregnancy Registry?

A. Complete the online reporting form anonymously at mycophenolaterems.com B. Send a letter to the manufacturer C. Call the Mycophenolate Pregnancy Registry by phone at 1-800-617-8191 D. Pregnancy reporting is automatically done upon filling an MPA prescription E. Unsure

Evaluation Questions

11. How confident are you in your treatment choices for the patient in the posttest?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Why does the US Food and Drug Administration require a Risk Evaluation and Mitigation Strategy (REMS) program for mycophenolic acid (MPA) prescription?

2. Patient education is an important component of the Mycophenolate REMS program. Which of the following types of counseling should be given to female patients of reproductive potential who may be started on MPA therapy?

3. Upon learning that a female patient who is taking MPA becomes pregnant, the pregnancy should be reported to the Mycophenolate Pregnancy Registry. Who can report the pregnancy?

5. The Mycophenolate REMS program focuses on multiple stakeholders: prescribers, patients, and other healthcare professionals. Which of the following best describes participation in the Mycophenolate REMS program?

6. Under which of the following circumstances would your recommend that a provider report a pregnancy to the Mycophenolate Pregnancy Registry?

8. AB indicates that she is single and has been dating. She would like to get pregnant and have children in the future. Which option when used alone is the most effective method of contraception and best choice for AB?

9. A pharmacy student is interning at a local pharmacy where AB picks up her prescriptions. The pharmacy intern notices MPA on AB's medication profile and recalls that there is a REMS program associated with this medication. What Mycophenolate REMS literature should the intern give to the patient?

Evaluation Questions

11. How confident are you in your treatment choices for the patient in the posttest?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Why does the US Food and Drug Administration require a Risk Evaluation and Mitigation Strategy (REMS) program for mycophenolic acid (MPA) prescription?

2. Patient education is an important component of the Mycophenolate REMS program. Which of the following types of counseling should be given to female patients of reproductive potential who may be started on MPA therapy?

3. Upon learning that a female patient who is taking MPA becomes pregnant, the pregnancy should be reported to the Mycophenolate Pregnancy Registry. Who can report the pregnancy?

5. The Mycophenolate REMS program focuses on multiple stakeholders: prescribers, patients, and other healthcare professionals. Which of the following best describes participation in the Mycophenolate REMS program?

6. Under which of the following circumstances would your recommend that a provider report a pregnancy to the Mycophenolate Pregnancy Registry?

8. AB indicates that she is single and has been dating. She would like to get pregnant and have children in the future. Which option when used alone is the most effective method of contraception and best choice for AB?

9. A pharmacy student is interning at a local pharmacy where AB picks up her prescriptions. The pharmacy intern notices MPA on AB's medication profile and recalls that there is a REMS program associated with this medication. What Mycophenolate REMS literature should the intern give to the patient?

Evaluation Questions

11. How confident are you in your treatment choices for the patient in the posttest?

« Return to Activity

Customers who Purchased
this Activity also Purchased